IDEXX Laboratories (IDXX) Stock Forecast & Price Target

$412.26 +3.23 (+0.79%)

(As of 12/20/2024 05:51 PM ET)

IDEXX Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 10 Analyst Ratings

Sell
0

Hold
2

Buy
8

Based on 10 Wall Street analysts who have issued ratings for IDEXX Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 10 analysts, 2 have given a hold rating, 7 have given a buy rating, and 1 has given a strong buy rating for IDXX.

Consensus Price Target

$539.63
30.89% Upside

According to the 10 analysts' twelve-month price targets for IDEXX Laboratories, the average price target is $539.63. The highest price target for IDXX is $650.00, while the lowest price target for IDXX is $435.00. The average price target represents a forecasted upside of 30.89% from the current price of $412.26.

Get the Latest News and Ratings for IDXX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors.

IDXX Analyst Ratings Over Time

Type	Current Forecast 12/22/23 to 12/21/24	1 Month Ago 11/22/23 to 11/21/24	3 Months Ago 9/23/23 to 9/22/24	1 Year Ago 12/22/22 to 12/22/23
Strong Buy	1 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	6 Buy rating(s)
Hold	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$539.63	$552.38	$582.25	$554.88
Forecasted Upside	30.89% Upside	31.72% Upside	14.90% Upside	0.15% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

AI breakthrough about to upend industry (Ad)

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

IDXX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

IDXX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

IDEXX Laboratories Stock vs. The Competition

Type	IDEXX Laboratories	Medical Companies	S&P 500
Consensus Rating Score	2.90	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	30.89% Upside	25,828.93% Upside	14.52% Upside
News Sentiment Rating	Positive News See Recent IDXX News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/2/2024	Leerink Partnrs 5 of 5 stars	D. Clark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
12/2/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$500.00	+18.55%
11/4/2024	Piper Sandler 2 of 5 stars		Reiterated Rating	Neutral ➝ Neutral	$520.00 ➝ $435.00	+3.71%
11/4/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$570.00 ➝ $481.00	+15.27%
10/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$630.00 ➝ $575.00	+20.64%
10/10/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$510.00 ➝ $500.00	+6.34%
Get the Latest News and Ratings for IDXX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.
7/25/2024	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Massaro Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$580.00	+23.05%
5/14/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$620.00 ➝ $596.00	+15.88%
4/9/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Outperform
1/17/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$500.00 ➝ $650.00	+25.68%
12/7/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$602.00	+15.42%
8/2/2023	Atlantic Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral	$610.00	+14.60%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 09:37 AM ET.

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Tuesday, December 17, 2024. Please send any questions or comments about these IDEXX Laboratories pros and cons to contact@marketbeat.com.

IDEXX Laboratories
Bull Case

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

IDEXX Laboratories, Inc. reported earnings per share of $2.80, exceeding the consensus estimate of $2.69, indicating strong financial performance and effective management.
The company achieved a net margin of 22.53%, showcasing its ability to convert revenue into profit efficiently, which is attractive for investors looking for profitability.
With a current stock price of $434.43, IDEXX Laboratories, Inc. has shown resilience in the market, reflecting investor confidence and potential for future growth.
Institutional investors own 87.84% of the stock, suggesting strong support from large financial entities, which can be a positive indicator of stability and trust in the company's future.
Recent upgrades from analysts, including a "strong-buy" rating from Leerink Partners, highlight positive market sentiment and potential for stock appreciation.

IDEXX Laboratories
Bear Case

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

The company's revenue of $975.50 million fell short of the consensus estimate of $980.32 million, indicating potential challenges in meeting market expectations.
Analysts have recently adjusted their price targets downward, with JPMorgan reducing its target from $630.00 to $575.00, which may signal concerns about future growth prospects.
Despite a strong earnings report, the stock has a high price-to-earnings ratio of 41.89, suggesting that it may be overvalued compared to its earnings, which could deter value-focused investors.
Insider selling activity, such as the recent sale of shares by Director Sophie V. Vandebroek, may raise concerns about the confidence of insiders in the company's future performance.
The company's beta of 1.37 indicates higher volatility compared to the market, which could pose risks for investors seeking stable investments.

IDXX Forecast - Frequently Asked Questions

: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for IDEXX Laboratories is $539.63, with a high forecast of $650.00 and a low forecast of $435.00.
: 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" IDXX shares.
: According to analysts, IDEXX Laboratories's stock has a predicted upside of 30.89% based on their 12-month stock forecasts.
: Over the previous 90 days, IDEXX Laboratories's stock had 1 upgrade by analysts.
: IDEXX Laboratories has been rated by research analysts at Barclays, JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Piper Sandler, and Stifel Nicolaus in the past 90 days.
: Analysts like IDEXX Laboratories more than other "medical" companies. The consensus rating score for IDEXX Laboratories is 2.90 while the average consensus rating score for "medical" companies is 2.81. Learn more on how IDXX compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

This page (NASDAQ:IDXX) was last updated on 12/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

IDEXX Laboratories (IDXX) Stock Forecast & Price Target